Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies

Journal of Affective Disorders

Volumn 227, Issue , 2018, Pages 103-108

  Nelson, J Craig ^a   Weiller, Emmanuelle ^b   Zhang, Peter ^c   Weiss, Catherine ^c   Hobart, Mary ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b H LUNDBECK A S   (Denmark)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Antipsychotic; Brexpiprazole; Core symptoms; Depression; Item analysis

Indexed keywords

BREXPIPRAZOLE; PLACEBO; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; SEROTONIN RECEPTOR AFFECTING AGENT; THIOPHENE DERIVATIVE;

ADULT; AKATHISIA; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LASSITUDE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PESSIMISM; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SADNESS; SOMNOLENCE; WEIGHT GAIN; COMBINATION DRUG THERAPY; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINOLONES; SEROTONIN AGENTS; THIOPHENES; TREATMENT OUTCOME;

EID: 85031732767     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2017.09.054     Document Type: Article

References (27)

1. ®). American Psychiatric Association, Washington, DC.
2. Bauer, M., El-Khalili, N., Datto, C., Szamosi, J., Eriksson, H., A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J. Affect. Disord. 127 (2010), 19–30.
3. Bech, P., Gram, L.F., Dein, E., Jacobsen, O., Vitger, J., Bolwig, T.G., Quantitative rating of depressive states. Acta. Psychiatr. Scand. 51 (1975), 161–170.
4. Bech, P., Tanghøj, P., Andersen, H.F., Overø K., Citalopram dose–response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl.) 163 (2002), 20–25.
5. Chandler, G.M., Iosifescu, D.V., Pollack, M.H., Targum, S.D., Fava, M., Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci. Ther. 16 (2010), 322–325.
6. Citrome, L., Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad. Med. 122 (2010), 39–48.
7. Cohen, J., Statistical Power Analysis for the Behavioral Sciences, second ed., 1988, Lawrence Erlbaum Associates, Publishers, Hillsdale, New Jersey.
8. Connolly, K.R., Thase, M.E., If at first you donʼt succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71 (2011), 43–64.
9. Guy, W., ECDEU Assessment Manual for Psychopharmacology, revised. 1976, National Institute of Mental Health, Rockville, Maryland.
10. Hamilton, M., A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960), 56–62.
11. Helmreich, I., Wagner, S., Mergl, R., Allgaier, A.K., Hautzinger, M., Henkel, V., Hegerl, U., Tadić A., Sensitivity to changes during antidepressant treatment: a comparison of unidimensional subscales of the Inventory of Depressive Symptomatology (IDS-C) and the Hamilton Depression Rating Scale (HAMD) in patients with mild major, minor or subsyndromal depression. Eur. Arch. Psychiatry Clin. Neurosci. 262 (2012), 291–304.
12. Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., Ito, N., McQuade, R.D., Mørk, A., Pehrson, A.L., Hentzer, M., Nielsen, V., Bundgaard, C., Arnt, J., Stensbøl, T.B., Kikuchi, T., Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin–dopamine activity modulator. J. Pharmacol. Exp. Ther. 350 (2014), 589–604.
13. Mauskopf, J.A., Simon, G.E., Kalsekar, A., Nimsch, C., Dunayevich, E., Cameron, A., Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depression Anxiety 26 (2009), 83–97.
14. Montgomery, S.A., Åsberg, M., A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979), 382–389.
15. Nelson, J.C., Portera, L., Leon, A.C., Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?. Biol. Psychiatry 57 (2005), 1535–1542.
16. Nelson, J.C., Portera, L., Leon, A.C., Assessment of outcome in depression. J. Psychopharmacol. 20:4 Suppl. (2006), 47–53.
17. Nelson, J.C., Mankoski, R., Baker, R.A., Carlson, B.X., Eudicone, J.M., Pikalov, A., Tran, Q.V., Berman, R.M., Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J. Affect. Disord. 120 (2010), 133–140.
18. Nelson, J.C., Zhang, P., Skuban, A., Hobart, M., Weiss, C., Weiller, E., Thase, M.E., Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment. Curr. Psychiatry Rev. 12 (2016), 278–290.
19. Ozaki, N., Otsubo, T., Kato, M., Higuchi, T., Ono, H., Kamijima, K., ADMIRE Study Group, Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery–Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study. Psychiatry Clin. Neurosci. 69 (2015), 34–42.
20. Patkar, A.A., Pae, C.U., Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs 27:Suppl. 1 (2013), S29–S37.
21. Reimherr, F.W., Martin, M.L., Eudicone, J.M., Marchant, B.K., Tran, Q.V., Pikalov, A., Marcus, R.N., Berman, R.M., Carlson, B.X., A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole. J. Clin. Psychopharmacol. 30 (2010), 300–305.
22. Spielmans, G.I., Berman, M.I., Linardatos, E., Rosenlicht, N.Z., Perry, A., Tsai, A.C., Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med., 10, 2013, e1001403.
23. Thase, M.E., Youakim, J.M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R.D., Carson, W.H., Nyilas, M., Sanchez, R., Eriksson, H., Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a Phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J. Clin. Psychiatry 76 (2015), 1224–1231.
24. Thase, M.E., Youakim, J.M., Skuban, A., Hobart, M., Zhang, P., McQuade, R.D., Nyilas, M., Carson, W.H., Sanchez, R., Eriksson, H., Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a Phase 3, randomized, double-blind study. J. Clin. Psychiatry 76 (2015), 1232–1240.
25. Thase, M.E., Zhang, P., Skuban, A., Hobart, M., Weiss, C., Weiller, E., Nelson, J.C., Efficacy of adjunctive brexpiprazole in patients with major depressive disorder: a clinical overview. Curr. Psychiatry Rev. 12 (2016), 291–301.
26. Tohen, M., Case, M., Trivedi, M.H., Thase, M.E., Burke, S.J., Durell, T.M., Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J. Clin. Psychiatry 71 (2010), 451–462.
27. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs, M.M., Balasubramani, G.K., Fava, M., STAR*D Study Team, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163 (2006), 28–40.